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Abstract
Successful control of falciparummalaria depends greatly on treatment with artemisinin com-
bination therapies. Thus, reports that resistance to artemisinins (ARTs) has emerged, and
that the prevalence of this resistance is increasing, are alarming. ART resistance has re-
cently been linked to mutations in the K13 propeller protein. We undertook a detailed kinetic
analysis of the drug responses of K13 wild-type and mutant isolates of Plasmodium falcipa-
rum sourced from a region in Cambodia (Pailin). We demonstrate that ART treatment in-
duces growth retardation and an accumulation of ubiquitinated proteins, indicative of a
cellular stress response that engages the ubiquitin/proteasome system. We show that resis-
tant parasites exhibit lower levels of ubiquitinated proteins and delayed onset of cell death,
indicating an enhanced cell stress response. We found that the stress response can be tar-
geted by inhibiting the proteasome. Accordingly, clinically used proteasome inhibitors
strongly synergize ART activity against both sensitive and resistant parasites, including iso-
genic lines expressing mutant or wild-type K13. Synergy is also observed against Plasmodi-
um berghei in vivo. We developed a detailed model of parasite responses that enables us
to infer, for the first time, in vivo parasite clearance profiles from in vitro assessments of
ART sensitivity. We provide evidence that the clinical marker of resistance (delayed para-
site clearance) is an indirect measure of drug efficacy because of the persistence of unvia-
ble parasites with unchanged morphology in the circulation, and we suggest alternative
approaches for the direct measurement of viability. Our model predicts that extending
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current three-day ART treatment courses to four days, or splitting the doses, will efficiently
clear resistant parasite infections. This work provides a rationale for improving the detection
of ART resistance in the field and for treatment strategies that can be employed in areas
with ART resistance.
Author Summary
Resistance to artemisinin antimalarials, some of the most effective antimalarial drugs, has
emerged in Southeast Asia, jeopardizing malaria control. We have undertaken a detailed
study of artemisinin-sensitive and-resistant strains of Plasmodium falciparum, the parasite
responsible for malaria, taken directly from the field in a region where resistance is devel-
oping. We compared these strains to lab strains engineered with either mutant or wild-
type resistance alleles. We demonstrate that in sensitive P. falciparum, artemisinin induces
growth retardation and accumulation of ubiquitinated proteins, indicating that the drugs
activate the cellular stress response. Resistant parasites, on the other hand, exhibit reduced
protein ubiquitination and delayed onset of cell death following drug exposure. We show
that proteasome inhibitors strongly synergize artemisinin activity, offering a means of
overcoming artemisinin resistance. We have developed a detailed model of parasite re-
sponses and have modelled in vivo clearance profiles. Our data indicate that extending
artemisinin treatment from the standard three-day treatment to a four-day treatment will
clear resistant parasites, thus preserving the use of this critical therapy in areas experienc-
ing artemisinin resistance.
Introduction
Malaria remains a scourge of humanity, affecting hundreds of millions of people and causing
~600,000 deaths each year [1]. Infection with Plasmodium falciparum is responsible for the
majority of severe malaria cases. During the asexual blood phase of its lifecycle, this protozoan
parasite invades, grows, and multiplies within red blood cells (RBCs). The initial stage of
intraerythrocytic growth (0–~24 h), during which the parasite exhibits an unfilled cytoplasm
in Giemsa-stained smears (referred to as “rings”), is characterized by a relatively slow metabo-
lism [2]. Ring-stage—infected RBCs are freely circulating and are thus the predominant stage
detected in samples taken from the peripheral blood of infected patients. From ~24 h to ~40 h
post-invasion (p.i.), in the “trophozoite” (or growing) stage, the parasite increases the rate of
uptake and digestion of hemoglobin from the host cytoplasm and shows a large increase in
metabolic rate. These mature parasites are characterized by the presence of hemozoin, the clas-
sic “malaria pigment” that results from hemoglobin digestion. Trophozoites are rarely observed
in the circulation of infected patients because of their adherence to endothelial cells and conse-
quent sequestration away from the circulation. Complications associated with cerebral seques-
tration are responsible for much of the malaria-related mortality and morbidity [3]. From ~40
h p.i., the parasite undergoes cytokinesis, forming a schizont that can contain up to 32 daughter
parasites (merozoites). At ~48 h p.i., the schizont bursts, releasing the merozoites and heralding
a new round of infection.
Artemisinin and its derivatives (collectively referred to as ARTs) have contributed enor-
mously to decreasing rates of malaria deaths over the last decade. ARTs are among the few
antimalarials that are active against ring-stage parasites, thus reducing the parasite burden in
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P. falciparum infections quickly and providing prompt therapy for severe infections [3]. The
ARTs contain an endoperoxide group that is critical for their activity. The mechanism of ART
action remains poorly understood, but ARTs are thought to be pro-drugs that need to be acti-
vated by opening of the endoperoxide ring, i.e., splitting the bonded oxygen atoms [4]. This
process requires the presence of heme or non-heme iron sources (and possibly other activators)
[5,6]. The activated ART intermediates are thought to react with susceptible (nucleophilic)
groups within parasite proteins and other cellular components, leading to parasite killing; how-
ever, the details remain unclear [7].
A disadvantage of ARTs is their short half-lives in vivo (~1–2 h). Accordingly, they are co-
administered with longer half-life partner drugs in ART combination therapies (ACTs) to pre-
vent recrudescence and to slow the emergence of resistance [8]. Current antimalarial control is
highly dependent on ACTs, which makes the emergence of ART resistance extremely concern-
ing [9–11]. Decreased sensitivity to ARTs, which manifests as delayed parasite clearance, is
now a problem in six Southeast Asian countries and is translating into decreased clinical effica-
cy in areas with concomitant partner-drug resistance [12,13]. Enormous efforts are underway
to contain and eliminate ART resistance.
Initially, monitoring ART resistance was hampered by the lack of a suitable in vitro correlate
[10]. Recently, assays employing short pulses mimicking clinical drug exposure [14–16], such
as the ring-stage survival assay (RSA), have provided a good correlation between reduced in
vitro sensitivity to dihydroartemisinin (DHA), the clinically relevant ART derivative, and de-
layed parasite clearance [15]. Combined with whole genome sequencing, this allowed the iden-
tification of mutations in a protein with a Kelch domain (i.e., β-propeller tertiary structure,
referred to as K13; PF3D7_1343700) [17] that are strongly associated with the slow-clearance
phenotype. A large Genome-Wide Association Study (GWAS) added further support to the
suggestion that K13 is the major locus controlling P. falciparum resistance to ARTs [18]. Recent
studies using genetic modification of the K13 locus have confirmed a central role for K13 muta-
tions in conferring ART resistance [19,20].
Here we present a detailed in vitro investigation of the drug responses of K13 wild-type and
mutant isolates of P. falciparum sourced from a region in Cambodia (Pailin) with a marked
penetrance of ART resistance [10,21]. Our results provide insights into the molecular basis of
ART action and resistance and point to a class of compounds that could be used to synergize
the activity of ARTs against both sensitive and resistant parasites. Modelling of parasite re-
sponses suggests alternate therapeutic regimens that should be vigorously pursued and pro-
vides tools that will immediately impact the way resistance is measured in the field.
Results
Whole Genome Sequencing of K13Wild-Type and Mutant Strains from
Pailin
We determined the whole genome sequences of four laboratory-adapted isolates of P. falcipa-
rum collected from adult patients enrolled in clinical trials conducted between 2009 and 2010
in the Pailin Referral Hospital in Cambodia [21]. High sequencing coverage with good map-
ping quality was achieved across all four genomes (mean sequence coverage of 77x and mean
mapping quality>30; see S1 Table). A Pairwise Distance matrix (5x5) built on 26,438 SNPs in
coding genes was used to generate a Neighbor Joining tree to examine isolate relatedness. The
isolates are quite divergent, with ~16,000 non-synonymous SNPs between any two isolates
(excluding var, rif, and stevors), and they exhibit multiple mutations in many of the drug-
resistance—related genes.
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One strain (PL2) encodes the wild-type K13 genotype, while the others (PL1, Y493H; PL5,
C580Y and PL7, R539T) represent three K13 mutants that are commonly observed in Cambo-
dia (S2 Table). A recent fine-structure analysis of parasite samples collected as part of the
large-scale Tracking Resistance to Artemisinin Collaboration (TRAC) study revealed that par-
ticular non-synonymous polymorphisms in apicoplast ribosomal protein S10 (arps10), multi-
drug resistance protein 2 (mdr2), ferredoxin (fd), and chloroquine resistance transporter (pfcrt)
are markers of a genetic background on which K13mutations are likely to arise, but individual-
ly they have little contribution to ART resistance [18,22]. Other GWAS have reported SNPs in
other genes that show association with the ART resistance phenotype [23–27]. The K13 mutant
and wild-type Pailin strains exhibited the expected SNPs at the arps10 (V127M) andmdr2
(T484I) loci and at one of the pfcrt (I356T) loci but showed variable sequences at the other loci
(see S2 Table for a summary of some relevant loci). Both K13 mutant and wild-type strains ex-
hibited the fd (D193Y) and pfcrt (N326S) SNPs that are strongly associated with ART resis-
tance founder populations [18]. The entire genomes for the four Pailin strains have been made
available through the European Nucleotide Archive (ENA) database under the accession num-
ber PRJEB8074.
K13 Mutants Exhibit Decreased ART Sensitivity during One-Third of the
Blood Cycle
We previously demonstrated that the sensitivity of laboratory strains of P. falciparum to ARTs
exhibits a complex dependence on drug exposure time and concentration [14]. For this work,
we used assays comprising very short drug pulses in an effort to mimic in vivo exposure and to
maximize the discrimination of subtle differences in parasite responses. We defined parasite vi-
ability as the fraction of the parasite population that survives drug exposure and is able to enter
the next parasite cycle. We found that the 50% lethal dose (LD50) and the viability at saturating
drug concentrations (the minimum viability, Vmin) are the most useful measures of cellular cy-
totoxicity, in agreement with other studies of ARTs and other drugs [15,28,29].
In the current work, tightly synchronized cultures of the four strains were subjected to 3-h
pulses of DHA at different stages of the asexual lifecycle (Fig 1A and 1B). Notably, the PL2
strain exhibits a low Vmin(3h) (<5%) across all stages of development (Fig 1A), confirming an
ART sensitive phenotype. In contrast, the PL1, 5, and 7 strains displayed 5%–60% survival over
the first 10–12 h p.i. (Fig 1A and 1B). The youngest ring stages (1.2 h p.i.) of the mutant strains
exhibited the greatest viability following drug exposure (Vmin(3h)>40%), as previously re-
ported [15], confirming the resistant phenotype of these strains. Of note, the PL2 and PL7
strains exhibit similar LD50(3h) values at 6 h p.i., but PL7 shows a higher capacity to survive
drug exposure (Vmin(3h) = 20%) (Fig 1A). Thus Vmin(3h) appears to be the more sensitive indi-
cator of the resistance genotype, as suggested previously [14].
We also monitored the drug response of mature parasites during their transition into the
next cycle (Fig 1A and 1B, b panels). Continuous in vitro culturing of parasite cultures results
in broadening of the age distribution over time. We measured the degree of broadening in this
study (e.g., the schizont-to-ring transition shown in the b panels in Fig 1). In agreement with a
previous study [14], ~80% of parasites that are synchronized to a 1-h window undergo the
schizont-to-ring transition over a period of ~4 h in the next cycle (i.e., ~48 h later). Late tro-
phozoites and early schizonts (average ages earlier than 6 h pre-invasion) of all strains exhibit
similar LD50(3h) values with no detectable survival when exposed to 0.7 μMDHA. By contrast
late-stage PL1, 5, and 7 schizonts (average ages later than 4 h pre-invasion), which form rings
during the course of the assay, exhibit increased LD50(3h) and Vmin(3h) values. This indicates
that the mutant strains have an increased ability to survive a clinically relevant drug pulse
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(0.7 μMDHA; 3 h) from -4 to +12 h p.i., encompassing almost one-third of the intraerythrocy-
tic cycle. The ability of late-stage schizonts to survive exposure is particularly important, con-
sidering each surviving parasite forms approximately ten daughter cells.
There are subtle differences between the responses of the different K13 mutants. These may
be due to additional genetic factors as well as to direct effects of the different mutations, as indi-
cated by a detailed reverse genetics analysis of the contribution of K13 to resistance in recent
Cambodian isolates and reference lines [20]. The time points for transition from ring to tro-
phozoites (i.e., the 50:50 point; indicated with "T" in Fig 1A and 1B) and the lifecycle durations
for the K13 mutant and wild-type parasites were: PL1 (30 h/49 h), PL5 (30 h/59 h), PL7 (27 h/
57 h) and PL2 (27 h/52 h), and 3D7 (22 h/41 h). Thus, among this small sample size, there
does not appear to be a simple correlation between the K13 mutation and the length of the ring
stage or of the intraerythrocytic cycle.
The Drug Responses of K13 Mutant andWild-Type P. falciparum Can
Be Modelled in Terms of a Cumulative Effective Dose
Our previous work with laboratory strains showed that ART-mediated killing requires that
parasites are exposed to a sufficient concentration of activated ART for a sufficient period of
time [14]. We defined a semi-empirical cumulative effective dose (CED) model that accounts
for the complex in vitro dependence of parasite viability on drug concentration and exposure
time and permits the interpretation of stage and strain-dependent differences in drug action in
terms of easy to understand underlying parameters. Here we analyzed the dependence of DHA
action on time of exposure in K13 wild-type (PL2) and K13 mutant (PL7, R539T) field strains
(Figs 1C and S1).
Fig 1. Stage-dependent in vitro DHA responses of Pailin strains. (A,B) Tightly synchronized PL2 and PL7 (A, red and blue, respectively) and PL1 and
PL5 (B, green and blue, respectively) cultures were assayed using 3-h DHA pulses across the blood cycle. The a panels show the variation of LD50(3h) and
Vmin(3h) during the first 32 h p.i. Time points corresponding to 50% trophozoites (T; filled cytoplasm in Giemsa stained smear) are indicated. The b panels
show the variation of LD50(3h) and Vmin(3h) across the schizont-to-ring transition. Post-invasion ages are normalized to those in the next cycle to account for
the different lifecycle durations of the different strains (49, 52, 59, and 57 h for PL1, 2, 5, and 7, respectively). Negative ages represent pre-invasion ages and
correspond to schizonts that are the indicated time from forming new rings. The midpoint of each box corresponds to the average parasite age at the start of
each assay, normalized to a value of zero when 50% of the parasites had formed rings. Colored bar widths reflect the relative parasite populations at the
beginning of each assay: schizonts (dark blue for PL7 and PL5, dark red for PL2, and dark green for PL1), rings (light blue for PL7 and PL5, light red for PL2,
and light green for PL1), and schizonts forming rings during the course of the assay (grey for all strains). (C) Tightly synchronized PL2 (red) and PL7 (blue)
cultures were subjected to DHA pulses of different durations at 2, 18, and 34 h p.i. Curves represent best fits obtained with the cumulative effective dose
(CED) model, with the parameters shown in Table 1. Dose response profiles for each exposure time are shown in S1 Fig.
doi:10.1371/journal.pbio.1002132.g001
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A 3-h exposure of PL2 (2 h p.i.) to 1.3 μMDHA is sufficient to reduce parasite viability to al-
most zero (Fig 1C, red). Remarkably, a significant fraction (20%) of PL7 early rings (Fig 1C,
blue) remain refractory to a 9-h exposure to 1.3 μMDHA, even though the LD50(9h) value (20
nM) suggests potent drug action at longer exposures; this further illustrates that Vmin is more
informative than LD50 in revealing the resistance-associated phenotype. Late rings (18 h p.i)
and trophozoites (34 h p.i.) from both strains show similar sensitivity to>3 h exposure to
DHA, but small differences in LD50 are evident at very short exposure times (Fig 1C).
We found that the CEDmodel is able to adequately describe the response of the Cambodian
strains to DHA at different stages of development, as well as the dependence of that response on
concentration and exposure time. That is, the CEDmodel can be used to generate the fitted
curves in Fig 1C and S1 Fig at the very early ring (2 h p.i.), the late ring (18 h p.i.) and the mid tro-
phozoite (34 h p.i.) stages. In this model, the effective dose (ED) is a saturable function of the
drug concentration and is defined by Km, the drug concentration resulting in half the effect of the
maximally effective dose, EDmax. Parasite viability is then a sigmoidal function of the cumulative
ED (EDcum) with slope γ and midpoint te;sat50 . The t
e;sat
50 value is the time taken to kill half of the par-
asites at saturated (and fixed) drug concentration. (See [14] for further explanation of the model).
The drug response of late rings and mid trophozoites was similar for both wild-type and mu-
tant strains and the analysis indicated similar CEDmodel parameters (Table 1; Fig 1C). Interest-
ingly, early rings from the K13 wild-type and mutant strains, which produce quite a different
drug response, exhibit similar Km values (14–19 nM; Table 1). This suggests that DHA initiates
an effect in both drug-sensitive and drug-resistant strains at a similar concentration, even in the
early ring stages. Since the ARTs are pro-drugs that are converted to the active form by reaction
with iron or heme [4,6], this suggests that all strains activate the drug with similar efficiency. By
contrast, there is a 3.5-fold increase in the te;sat50 values for DHA for early ring stage PL7 parasites
(Table 1), and this underlies most of the difference in the response of this strain. As previously
demonstrated for laboratory strains [14], such an increase in te;sat50 manifests as an increase in the
lag time for drug action. In other words, there is a longer delay following drug treatment before
the onset of the killing of the K13 mutants. Since te;sat50 ¼ EDcum50 =EDmax (where EDcum50 is the cumu-
lative ED required to kill 50% of the parasites [14]), this indicates that PL7 requires longer expo-
sure to an effective dose to induce killing (or the maximal effective dose produced is less). This
difference is expected to be very important in vivo given the very short in vivo half-lives of ARTs.
K13 Mutant andWild-Type Parasites Exhibit Similar DHA-Mediated
Cytostatic Effects That Precede Killing
A number of studies have suggested that ARTs can exert cytostatic effects at sub-lethal
concentrations [30,31]. Here we have used the RNA-binding dye SYTO-61 (which can readily
Table 1. CEDmodel parameters for PL2 and PL7 strains.
Parameter Parasite Strain and Stage
Ring (2 h p.i.) Ring (18 h p.i.) Troph (34 h p.i.)
PL2 PL7 PL2 PL7 PL2 PL7
γ 2.6 1.9 2.6 3.6 ND 2
te;sat50 (h) 1.4 4.9 0.9 1.2 ND 0.2
Km (nM) 19 14 60 88 ND 16
ND: parameters could not be reliably determined
doi:10.1371/journal.pbio.1002132.t001
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distinguish parasites of different ages [30]) to determine whether the parasites that survive
DHA exposure exhibit growth retardation. (See Materials and Methods for labelling strategy).
We initially examined growth effects in the laboratory strain, 3D7, at the ring stage of devel-
opment, where it exhibits 10-fold lower sensitivity to a 3-h DHA pulse compared to the tro-
phozoite stage [14]. We found that mid-ring (6 h p.i.) and later ring (18 h p.i.) stage parasites
that survive exposure to a 4-h drug pulse exhibit a dose-dependent decrease in the intensity of
the SYTO-61 signal following treatment (Fig 2A, green curves). The IC50(4h) for the growth re-
tardation effect was similar across the ring stage (~10 nM) and was 5- to 10-fold lower than the
corresponding LD50(4h) value (i.e., cytotoxic effect). Examination of the population profile of
Fig 2. DHA induces growth retardation prior to killing. (A, C) DHA-induced decrease in the SYTO-61
signal of viable parasites. Tightly synchronized 3D7 (A) and PL2 and PL7 (C) parasites were subjected to 4-h
(A) or 3-h (C) DHA pulses at the ring-stage ages indicated in the figure. The median SYTO-61 signals of
viable parasites were determined in the next cycle (see Materials and Methods). The concentration
dependence of the SYTO-61 signal (growth effects; green symbols) is compared with that of parasite viability
(grey symbols). Dashed green and grey lines represent the IC50 and LD50 values associated with each
exposure time. Error bars correspond to the range of duplicates. (B,D) Changes in the SYTO-61 staining
profile of viable parasites after drug exposure. 3D7 parasite (6 and 18 h p.i., B) were subjected to 4-h DHA
pulses at 63 and 16 nM, respectively. Alternatively PL2 and PL7 late rings (18 h p.i.) were subjected to 1.5, 3,
and 6-h DHA pulses (16 nM; D). The SYTO-61 signals were measured by flow cytometry in the next cycle.
The SYTO-61 distributions of the viable population (dark green) are compared with those of untreated
parasites (light green). Asterisks highlight an absolute increase in the number of younger parasites, indicating
growth retardation.
doi:10.1371/journal.pbio.1002132.g002
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SYTO-61 staining shows an absolute increase in the number of viable parasites with decreased
SYTO-61 signals in the drug-treated samples compared to the untreated controls (Fig 2B, as-
terisks). This indicates that the decrease in the SYTO-61 signal following drug exposure reflects
drug-induced growth retardation rather than selective killing of the oldest parasites.
Similarly for both the K13 wild-type (PL2) and R539T mutant (PL7) strains, early ring-
stage parasites (2 h p.i.) that survive drug exposure exhibit dose-dependent growth retardation
(Fig 2C, green curves). Interestingly, the two strains exhibit similar IC50(3h) values for growth
retardation (10 nM) despite their very different sensitivities to killing (LD50(3h) = 10 and
>1000 nM for PL2 and PL7, respectively; Fig 2C, compare green and grey curves). These
IC50(3h) values remain relatively constant throughout the ring-stage, with the maximum effect
evident in late rings (Fig 2C, right panels).
We compared the effect of the time of exposure to drug on growth retardation and viability.
The response of the PL2 and PL7 strains at late-ring stage to exposure to DHA for a very short
period (1.5 h) is similar, and mainly comprises growth effects without loss of viability (Fig 2D).
Differences in viability manifest at longer exposures (Fig 2D, 3 and 6h). While PL2 parasites suc-
cumb to longer drug exposure, the growth-retarded PL7 parasites are able to withstand drug
pressure for longer. This demonstrates that it is the ability of the growth-retarded PL7 parasites
to withstand subsequent drug pressure that is responsible for their resistance phenotype.
Drug-induced growth retardation effects are important as they will influence the stage at
which surviving parasites are exposed to recommended ART regimens, which often include
daily doses administered 24 h apart. We quantitated the magnitude of this growth effect by
subjecting tightly synchronized PL7 parasites (1.5 h p.i.) to a 3.5-h DHA pulse (1 μM) and peri-
odically examining parasite morphology by Giemsa staining over a period of 40 h, following
the drug pulse. At times>30 h, two distinct parasite populations were identified corresponding
to those containing hemozoin (predominantly trophozoite morphologies) and those with
pyknotic or early ring morphologies (Fig 3A). The fraction of parasites exhibiting a trophozo-
ite-like appearance (30%; n>100 parasites) matched the viability as measured by flow cyto-
metric analysis in the cycle following the drug pulse (28%), indicating that these trophozoites
represent the viable population and confirming this as a simple method for measuring loss of
viability (i.e., parasites rendered incapable of reproduction) in the same cycle as the drug treat-
ment. A comparison of the sizes (areas of Giemsa-stained parasites) of the surviving trophozo-
ites with those from an untreated culture shows that the surviving parasites were, on average,
delayed 6 h in their progression through the cycle and exhibited a broader age distribution
(Fig 3A and 3B).
Unviable K13 Mutant andWild-Type Parasites Exhibit Differential Rates
of Conversion to Pyknotic Forms
The above analysis indicated that unviable parasites (i.e., incapable of reproduction) can exhib-
it normal ring morphologies for some time after exposure to ART. We examined the timing of
the appearance of pyknotic forms in Giemsa smears, following a DHA pulse, to determine
whether the differential drug response of sensitive and resistant strains also influenced the rate
of generation of pyknotic forms. Early ring-stage parasites (1.5 h p.i.) were pulsed with 1 μM
DHA for 3.5 h to generate unviable parasites (100% and 72% of PL2 and PL7 parasites, respec-
tively, based on flow cytometric analysis in the cycle following the drug pulse), and parasite
morphology was quantitated (from Giemsa smears) every 2–4 h following the drug pulse. Sur-
prisingly unviable PL2 and PL7 parasites retained a ring-like morphology 13 h after the drug
pulse, with pyknotic forms comprising<10% of the unviable population (Fig 3C and 3D). A
significant fraction of unviable parasites from both strains (12% and 28% for PL2 and PL7,
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respectively) exhibited ring-like morphologies 35 h following the drug pulse. Interestingly, the
half-time for adoption of pyknotic morphology was significantly longer for PL7 (32 h) than for
PL2 (23 h). This indicates that unviable resistant parasites retain a ring-like morphology for
longer following DHA treatment. In vivo, these unviable K13 mutant parasites may remain in
the blood stream for longer.
Cytostatic effects reflect a cellular stress response that engages the
ubiquitin-proteasome pathway
The growth retardation caused by exposure to DHA is reminiscent of the cell stress response
observed in other organisms. In other systems, cellular insults can result in protein unfolding,
culminating in polyubiquitination of proteins and their destruction via the proteasome. Inter-
estingly, a very recent analysis of the transcriptomes of parasite samples collected as part of the
Fig 3. Quantitation of growth retardation and transition to pyknotic forms following DHA treatment. (A) Early ring-stage PL7 parasites (1.5 h p.i.) were
treated with a 3.5 h DHA pulse (1 μM) and the morphology of parasites (Giemsa smears) examined at 31 and 35 h after the drug pulse. Representative
images of untreated and treated parasites are shown. The proportion of the parasite population corresponding to trophozoites (hemozoin-containing
parasites) and non-trophozoites (rings or pyknotic forms) are indicated in the figure. (B) The size distribution of viable parasites (hemozoin-containing) in the
drug-treated culture was quantitated and compared with untreated cultures at the indicated times after the drug pulse (n >50 per sample). Late rings are
larger than early trophozoites and were counted as a separate category (filled grey bars). (C) PL2 (red) and PL7 (blue) parasites (1.5 h p.i.) were rendered
unviable by treatment with a DHA pulse (1 μM, 3.5 h) and the fraction of unviable parasites exhibiting pyknotic morphology was quantitated (filled symbols).
Open symbols denote untreated parasites. (D) Representative images of untreated PL2 parasites and treated unviable parasites showing ring-like and
pyknotic morphologies (fraction of each morphology indicated).
doi:10.1371/journal.pbio.1002132.g003
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TRAC study provided evidence for up-regulation of protein homeostasis genes (such as the
ubiquitin-proteasome pathways) that correlates with delayed clinical clearance of parasites
[32]. To determine the level of protein damage following ART treatment, we sought to deter-
mine the level of ubiquitinated proteins in parasite extracts.
We found that we were not able to reliably measure the parasite-associated signal above the
host RBC background at the very early ring stage (mean fold change = 0.9 ± 0.2; n = 5). There-
fore we examined effects in trophozoites (which have much higher levels of protein ubiquitina-
tion) where K13 wild-type and mutant trophozoite stage parasites show less dramatic, but still
measureable differences in response to very short pulses of DHA (see Fig 1C, 34 h p.i). We
found that this differential response was more pronounced when parasites were treated with
the less potent parent drug, artemisinin (qinghaosu; QHS). We found that a very short pulse
(90 min) of QHS killed PL7 much less efficiently than PL2 and 3D7 (LD50(1.5h) values of 857,
208, and 153 nM, respectively.
To determine the effect of QHS treatment on cell stress levels, infected RBCs were saponin-
lysed to release the soluble RBC cell contents and parasite extracts were subjected to SDS-PAGE
and probed with an antibody that recognizes ubiquitin (Fig 4A). A profile of ubiquitination was
observed similar to that reported previously [33], with protein ubiquitination in trophozoites no-
tably higher than in uninfected RBC ghosts. The level of protein ubiquitination increased signifi-
cantly upon ART treatment (90 min pulse of 1 μMQHS), consistent with engagement of the
ubiquitin-proteasome system. The level of protein ubiquitination was higher in ART-treated
3D7 and PL2 parasites than in PL7 parasites (Fig 4A), consistent with the resistant parasites
experiencing a lower level of cellular stress. By contrast, a 90 min pulse treatment with 20 nM
WR99210 (a concentration sufficient to cause 100% killing) had no effect on the level of ubiquiti-
nation (Fig 4A, right panel). A quantitative analysis of several experiments is presented in Fig 4B.
Fig 4. Ubiquitination of P. falciparum proteins following ART treatment. Uninfected RBCs or
trophozoite-infected RBCs (24–44 h p.i.) (3% hematocrit) of 3D7, PL2, and PL7 strains were incubated with
1 μMQHS or 20 nMWR99210 for 90 min at 37°C. Cell extracts were subjected to SDS-PAGE and western
blotting and probed with anti-ubiquitin IgG with ECL detection, then stripped and re-probed with anti-
PfGAPDH. (A) Representative western blots. (B) Densitometric analysis of the anti-ubiquitin signal for at least
nine QHS and threeWR99210 experiments. Significance was determined using a Student’s t test. * p <0.05;
*** p <0.005.
doi:10.1371/journal.pbio.1002132.g004
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Cellular Stress Pathways Can Be Targeted to Enhance ART Activity
against Both Sensitive and Resistant Parasites
Given the evidence for accumulation of ubiquitinated proteins following ART treatment, we
examined the effects of inhibitors of the proteasome; a proteinase complex that plays a critical
role in degrading unfolded proteins. Proteasome complexes are present in both the host and
parasite cytoplasm, though selective inhibition of the host proteasome does not affect parasite
growth or replication [34,35]. Epoxomicin is a well-characterized and highly specific protea-
some inhibitor [36] and has activity against the P. falciparum proteasome [37]. Epoxomicin
showed activity against all stages of the field strains, when used alone, with maximal potency
against early ring-stages (see y-axis intercepts in right panels in Figs 5 and S2). This activity
was independent of K13 genotype.
Fig 5. Synergy of DHA and a proteasome inhibitor against P. falciparum. The interaction of DHA and
epoxomicin (Epo) was examined using (A) 3D7 and (B) PL1 parasites at the ages indicated. Left panels in (A
and B) show the dose-responses to DHA (blue symbols) and the influence of sublethal concentrations
(indicated) of epoxomicin. Right panels in (A and B) show isobolograms for the epoxomicin-DHA pair at the
50% LD50(3h) level. The dashed line is plotted between the LD50(3h) of each drug when used alone,
emphasizing the concave nature of many of the isobolograms. The absence of a dashed line indicates the
LD50(3h) value of one of the drugs was outside the range of concentrations examined. Error bars, where
present, correspond to the range of duplicates.
doi:10.1371/journal.pbio.1002132.g005
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We examined the interaction between DHA and epoxomicin by examining the effect of
epoxomicin on the dose response profile of DHA, and by measuring the isobologram for the
pair of drugs [38] at the 50% lethal dose level. We initially examined 3D7 parasites. Unlike the
Pailin strains, early ring-stage 3D7 parasites (2 h p.i.) exhibit ART hypersensitivity [14] and we
observed no interaction between DHA and epoxomicin at this stage (Fig 5A, top) panel. In
contrast, a sub-lethal concentration of epoxomicin (18 nM) enhances the potency of DHA
~10-fold against the ring-stage of 3D7 (Fig 5A, middle panel); this is illustrated by the concave
shape of the LD50 isobologram. This suggests that the proteasome inhibitor overcomes the cell
defense systems that protect the mid-ring stage of 3D7.
We next examined the ability of epoxomicin to synergize the action of DHA against the K13
mutant isolate, PL1. A pronounced synergistic interaction is evident at early ring and ring
stages (Fig 5B). Notably, some synergism is also evident in the trophozoite stage (Fig 5B, bot-
tom panel). This is in stark contrast to the effect of hemoglobinase inhibitors, which produce
strong antagonistic interactions in the trophozoite stage [30]. We observed a similar synergistic
interaction with two other K13 mutant strains (PL5 and 7), with pronounced synergism at
early-ring and ring stages (S2B and S2C Fig). The synergistic effect was less pronounced but
still evident in the Pailin K13 wild-type isolate (PL2) (S2A Fig).
Very recently, modification of the P. falciparum K13 locus in defined genetic backgrounds
was used to demonstrate a central role for K13 mutations in conferring ART resistance [20].
These studies included a laboratory-adapted K13 mutant isolate from Cambodia (Cam3.II_
R539T) and a reverted transfectant in the same line, in which the K13 wild-type genotype has
been restored. We examined the sensitivity of these parasites to DHA at different stages of
intraerythrocytic development (S3 Fig). Cam3.II exhibited marked resistance to DHA in the
very early ring-stage with a Vmin(3h, 1 μM) value of 69% and an LD50 value of>>1 μM (S3 Fig),
while the Cam3.II_rev line showed markedly enhanced sensitivity with a Vmin(3h, 1 μM) value
of 8% and an LD50 value of 47 nM, in good agreement with the recent report [20]. We examined
the interaction of epoxomicin with DHA against Cam3.II_R539T and Cam3.II_rev. Epoxomicin
exhibited very strong synergism with DHA in the very early ring-stage of the Cam3.II_R539T
isolate (S3 Fig), consistent with the proteasome inhibitor overcoming the K13-mediated resis-
tance mechanism. However, synergism was also observed in the ring and trophozoite stages of
Cam3.II and in all stages of the revertant line (S3 Fig). This confirms that proteasome inhibitors
can enhance the activity of ARTs against both sensitive and resistant parasites.
Proteasome inhibitors are used clinically in humans to treat myeloma [26]. We examined the
effect of two of these compounds, Carfilzomib, an epoxyketone, and Bortezomib, a peptide bor-
onate [39]. Like epoxomicin, Carfilzomib was potent against all strains and stages examined and
exhibited strong synergism with DHA, particularly in the less sensitive, very early ring stage (S4
Fig). Similarly, the clinically used proteasome inhibitor Bortezomib exhibited strong synergism
with DHA (S5 Fig). These results confirm that the proteasome is involved in the parasite's re-
sponse to DHA and that inhibiting its activity enhances the level of killing of the parasite.
A Proteasome Inhibitor Acts Synergistically with DHA In Vivo
Proteasome inhibitors such as Carfilzomib have previously been tested for in vivo activity
against a murine model [40]. While the activity of Carfilzomib alone against P. berghei is low,
we were interested to determine whether sub-lethal concentrations of Carfilzomib might syner-
gize the activity of DHA in the P. bergheimouse model. In agreement with a previous report
[40], we found that treatment with up to 1 mg/kg of Carfilzomib monotherapy had no toxic
effects, but also had no beneficial effects in reducing parasite burden (Fig 6A). We found that
DHA treatment alone (initiated at ~1% parasitaemia) at a dose of 5 or 10 mg/kg/day gave
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a moderate decrease in parasite burden (Fig 6B and 6C), while 15 or 20 mg/kg was sufficient to
abrogate the parasite burden (S6A and S6B Fig). By contrast, a combination of Carfilzomib
(0.5 or 1 mg/kg/day) and DHA (5 mg/kg/day) was associated with a significant reduction in
the parasite growth (Fig 6B, red and blue curves) while a combination of Carfilzomib (0.5 or 1
mg/kg) and DHA (10 mg/kg) almost completely abrogated the parasite burden (Fig 6C, red
and blue curves). Of particular interest is the observation that a combination of DHA (5 mg/
kg) + Carfilzomib (1 mg/kg) (S6C Fig, green curve) or DHA (10 mg/kg) + Carfilzomib (0.5 and
1 mg/kg) (S6C Fig, blue and purple curves) largely abrogated the parasites in the circulating re-
ticulocytes, the blood cell preferentially parasitized by P. berghei. This further confirms the
role of the proteasome in protecting malaria parasites against the toxic effects of DHA and
points to a possible means of synergizing the activity of ARTs in vivo, using repositioned
proteasome inhibitors.
Modelling In Vivo Parasite Clearance
The availability of the data from our extensive kinetic analysis of the K13 wild-type and mutant
Pailin strains offers the possibility of modelling the drug response of resistant and sensitive par-
asites at different exposure times and concentrations in vitro and also of extending this analysis
to infer behavior in vivo [14]. To do this, we extended the CED mathematical model to take
into account the age- and exposure-time—dependence of the drug responses of the sensitive
and resistant strains, as well as drug-induced growth retardation and population broadening.
We provide an Excel spreadsheet that presents the Mathematical Model in a user-friendly for-
mat (S1 Spreadsheet). We have provided a presentation in Prezi that explain the steps involved
in using the spreadsheet (https://prezi.com/9xo9b8igvjzl/).
We applied the model to predict parasite clearance rates in vivo during a three-day course of
ART monotherapy. We assumed DHA is applied at a rate of 2 mg/kg at 0, 24, and 48 h, i.e., in a
typical regimen [41]. We took into account the age distribution of parasites at the time of patient
presentation (which varies depending on disease severity [32,42,43]), the age-dependence of
drug action (CED parameters, from Table 1), the broadening of the age distribution with time
Fig 6. In vivo synergy between DHA and Carfilzomib in a P. bergheimousemodel. Balb/c mice were infected with 106 parasites (P. berghei) and
treatment was initiated at ~1% parasitaemia (i.e., day 3), indicated with an arrow. Data represent averages of data from three independent experiments. (A)
Carfilzomib alone has no effect on parasite growth at doses of 0.5 and 1 mg/kg, but has a slight antimalarial effect at 1.5 mg/kg. (B) Treatment with DHA (5
mg/kg) + Carfilzomib (0.5 mg/kg) reduces parasite growth, while DHA (5 mg/kg) + Carfilzomib (1 mg/kg) prevents parasite growth. (C) DHA (10 mg/kg)
+ Carfilzomib (0.5 or 1 mg/kg) also reduces parasitemia by 2- to 3-fold. Error bars represent SEM and * and *** represent, respectively, p <0.05 and p <0.01,
after Bonferroni correction for multiple testing.
doi:10.1371/journal.pbio.1002132.g006
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(S1 Appendix), and drug-induced growth effects (from Figs 2 and 3). This simulation evaluates
the in vivo consequences of the different in vitro drug responses of ring-stage K13 wild-type and
mutant parasites (see S1 Appendix). Strikingly, the first and third ART doses given to a hypo-
thetical patient with a PL7-like (resistant) infection result in<10-fold reduction of viable para-
sites (Fig 7). In contrast, the PL2 (sensitive) strain shows a 50-fold reduction in parasite burden
at the corresponding times (Fig 7A, orange curves). As a result, the parasite burden in a PL7-like
infection is ~50-fold higher after a three-day treatment. As a consequence of drug-induced syn-
chronization and growth retardation, the parasite age distribution at 72 h consists
Fig 7. Delayed parasite clearance of resistant strains reflects both reduced killing and delayed
removal of unviable parasites. (A) Viable parasite load during DHA treatment regimen. The number of total
(circulating and sequestered; orange curves) and circulating (grey curves) viable parasites during DHA
therapy in hypothetical patients presenting with ring-stage PL7- and PL2-like infections were simulated using
CEDmodel parameters and an in vivo DHA pharmacokinetic profile (see S1 Appendix, S3 Table). Arrows
indicate the times of drug administration. (B) Influence of unviable parasite removal on parasite clearance
profiles. The circulating unviable parasites in (A) in the PL2 and PL7-like infections (red and blue curves,
respectively) were modelled to disappear from circulation with a half-life of 5 h (dashed curves) or exhibit
more complex removal (solid curves) involving strain-dependent (1- and 3.5-h half-lives for PL2 and PL7), in
addition to a strain-independent (3-h half-life) component. Symbols correspond to median circulating parasite
loads from patients in Pailin (blue) andWang Pha (red) [41]. (C) Contribution of unviable parasites to parasite
clearance curves. The solid curves represent the simulated parasite clearance curves shown in Fig 7B
incorporating the complex clearance of unviable parasites. The dashed curves correspond to the total
number of unviable parasites at each time point and the dotted curves to the unviable parasites produced
during the course of the first treatment (i.e., formed during the first 24 h).
doi:10.1371/journal.pbio.1002132.g007
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predominantly of late rings (S7 Fig). Importantly, administration of an additional dose at 72 h is
predicted to decrease the parasite load of a PL7-like infection at 96 h to the level observed with a
three-day treatment of a PL2-like sensitive infection (Fig 7A, asterisks). In consequence, we pre-
dict that a four-day course of ACT will significantly reduce the incidence of treatment failure in
areas with ART resistance.
In field studies, Giemsa smears are used to monitor the effectiveness of drug treatment.
This approach, however, only detects circulating rings and not mature, sequestered parasites.
Our simulation incorporates sequestration and shows that the density of circulating viable
parasites will exhibit time-dependent fluctuations over many orders of magnitude, particular-
ly in the period 24–48 h after treatment (Fig 7A, grey curves). These fluctuations are not evi-
dent in real patient-averaged data [41], as shown in Fig 7B (symbols), nor in data from
individual patients [42]. We posit that this discrepancy arises because our initial simulation
assumes that unviable parasites are immediately removed from the circulation. Splenic clear-
ance represents the major in vivo route for removing killed rings [44,45], with unviable para-
sites persisting for>60 d after ART chemotherapy in splenectomized patients [46]. Our
analysis in Fig 3C and 3D shows that unviable rings retain their ring-like morphologies for
many hours, indicating splenic clearance would similarly occur over a period of hours. Esti-
mates of the half-life for splenic clearance of dead parasites range from 3 to 6 h [47,48]. Incor-
porating a clearance half-life of 5 h for removal of unviable parasites (Fig 7B, dashed lines)
produces clearance profiles that resemble those measured in patients exhibiting delayed clear-
ance from Pailin (blue symbols), but predicts that both the mutant and wild-type strains
would be removed from the circulation at similar rates, despite clear differences in killing (Fig
7A, orange curves). This strongly suggests the existence of additional strain-dependent factors
involved in the clearance of unviable parasites.
A possible explanation for a strain-dependent effect is that unviable parasites persist in the
circulation (with a ring-like morphology) before changing their physico-mechanical properties
sufficiently to initiate splenic clearance. This is consistent with the delayed appearance of
pyknotic forms following treatment of cultures with DHA (Fig 3C and 3D), which indicates
that unviable parasites retain ring-like morphologies for an extended period. It is also of inter-
est that the half-time to pyknosis is particularly extended in PL7 (K13 mutant) parasites. In-
deed, incorporation of an additional strain-dependent term, as well as maintaining a strain-
independent splenic clearance rate, permits improved predictions of the observed parasite
clearance curves (Fig 7B, solid curves).
This analysis has implications for monitoring parasite clearance times in the field. We antic-
ipate that killed rings that retain a ring-like morphology would persist in circulation and be
counted in Giemsa smears. Moreover, unviable resistant parasites would persist for longer in
the circulation. Our simulations indicate that in clinical practice, the ring-stage parasites that
are detected in Giemsa smears, after ART treatment, likely comprise mainly unviable parasites
(Fig 7C, dashed curves). A significant fraction of these will have been rendered unviable after
the first dose (dotted lines), especially in fast clearing, sensitive strains. Consequently, the rela-
tionship between the in vitro marker of resistance (decreased parasite killing) and the clinical
marker of resistance (delayed parasite clearance) is more complex than previously appreciated.
To examine the potential effect on the interpretation of field studies, we simulated a scenario
to examine the effect of a split-dose ART treatment on parasite clearance. A recent clinical trial
reported that a split-dose ART treatment regimen did not improve parasite clearance times for
malaria infections with either ART-sensitive or-resistant P. falciparum [49]. Indeed, the simu-
lations (see S1 Appendix, S4A Fig) show that splitting the dose will have only a very small effect
on the parasite clearance curves. By contrast, there is a very large effect on the number of
viable parasites. The simulation predicts that a split-dose regimen should reduce the load of
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a resistant (PL7-like) infection to a level well below that observed in a sensitive (PL2-like) infec-
tion subjected to a standard treatment.
Direct quantitation of circulating viable parasites during drug treatment would complement
the current parasite clearance approach for classifying ART resistance in the field. Our simula-
tions indicate that the fraction of circulating parasites that are viable 3 h after commencement
of treatment is independent of the typical variation of serum DHA concentrations (Cmax = 0.5
to 20 μM [9,49]) and represents a useful parameter for characterizing the in vivo response of a
particular strain (S8 Fig). Within this short period of time, there is sufficient difference in loss
of parasite viability to distinguish between sensitive and resistant infection, without the compli-
cating effects of significant loss of viable parasites due to sequestration, or from splenic clear-
ance of unviable parasites, which complicates the interpretation at longer times (S8 Fig).
Discussion
It is generally accepted that ARTs are pro-drugs. That is, they are administered in an inactive
form and are activated by reductive cleavage of the endoperoxide ring (see reviews [4–6,50]).
The resulting free radicals are thought to react with susceptible groups within a range of parasite
proteins and other components, leading to cellular damage and killing. When applied in vitro as
clinically relevant short pulses, ARTs are significantly more active against trophozoite-stage par-
asites than against the mid-ring stage [14]. This likely reflects, in part, the higher availability of
iron-containing activators (as a result of hemoglobin degradation) at the trophozoite stage.
However, the rate and efficiency of parasite killing will also depend on the ability of the parasite
to defend itself against cellular damage. In this work, we have undertaken a careful analysis of
the response of K13 wild-type and mutant parasites to ART at different stages and at different
exposure times with a view to understanding and overcoming the resistance mechanism.
We found that at low concentrations of DHA, we were able to distinguish cytostatic effects
(growth inhibition) from cytotoxic activity (which renders the parasites incapable of reproduc-
ing). Interestingly, while different stages and strains of P. falciparum exhibit very different levels
of sensitivity to killing by DHA, the IC50 values for induction of the growth effects are similar.
This is consistent with the suggestion that cytostatic effects are initiated as soon as the toxic in-
sult is detected, with downstream killing, if and when the cell defense systems are overwhelmed.
The observed growth retardation is reminiscent of the cellular stress responses reported in
other organisms. For example, oxidative and non-oxidative stress events activate an unfolded
protein response, leading to shut-down of protein translation and other metabolic pathways
[51,52]. While P. falciparum appears to lack the genes for a classical unfolded protein response
[53], it possesses a functional ubiquitin-proteasome system [33,54] and has been shown to un-
dergo eIF2-α–mediated arrest of protein translation, leading to stalling of growth [55].
Consistent with this, we found that the level of ubiquitinated proteins is increased upon ex-
posure to an ART insult, indicating that activated ART damages proteins and initiates a stress
response that engages the ubiquitin-proteasome system. By contrast, exposure to a lethal pulse
of an anti-folate inhibitor (WR99210) had no effect on the level of ubiquitination. Because
ARTs are very short-lived in vivo, the growth stasis that is induced by ART exposure would
buy time for the proteasome to degrade ubiquitinated proteins, enabling survival until the ART
concentration has declined.
Resistance could arise as a result of decreased ART activation or via the mitigation of down-
stream damage. ART-sensitive and-resistant Pailin strains show similar Km values for ART-
induced killing and similar IC50 values for growth inhibition, indicating similar rates of ART
activation. By contrast the extended lag phase before onset of killing and the delayed conver-
sion to the pyknotic state exhibited by K13 mutants, as well as the lower levels of ubiquitinated
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proteins and the synergism with proteasome inhibitors, are consistent with the suggestion that
an enhanced cellular stress response underlies resistance. We present a possible model for ART
action and the cell stress response in Fig 8, in which death occurs when the level of damage
overwhelms the parasite's proteasome system.
As predicted by this model, we found that proteasome inhibitors, such as epoxomicin, Car-
lifzomib, and Bortezomib, markedly synergize the action of DHA. In the laboratory strain 3D7
this effect is particularly marked in the mid-ring stage of development, when the parasite
shows low sensitivity to DHA, but is not evident in the very early ring stage, when the parasite
exhibits ART hypersensitivity. In the K13 mutant strains, PL1, 5, and 7, the synergism is partic-
ularly marked at the very early ring stage when these parasites are especially resistant to DHA.
In an effort to distinguish the role of the K13 gene product from other contributing genetic dif-
ferences, we examined the level of synergism in a Cambodian K13 mutant (Cam 3.II) and a ge-
netically matched K13 wild-type (reverted) transfectant. The revertant shows very early ring
stage sensitivity that is similar to that that observed for the Pailin wild-type strain (PL2). Epox-
omicin markedly synergized the activity of DHA against the very early ring stage of the K13
mutant, but also increased its activity against the revertant. This suggests that a proteasome-
engaging cell stress response is involved in protecting both sensitive and resistant parasites
from the action of ARTs, but that this response is more effective in the K13 mutant parasites.
Our data suggest that proteasome inhibitors could provide a synergistic combination with
ARTs that would enhance their effectiveness against both K13-mutant and wild-type parasites.
Fig 8. Model of killing and survival-promoting events following treatment with ART. ART is activated by an Fe(II) source (e.g., heme released from
hemoglobin degradation or from the cellular labile iron pool) to produce activated ART (ART*), which is reactive, leading to cellular damage and ultimately to
parasite death (shown in black). The parasite mounts a stress response, that manifests as growth retardation and engagement of the proteasome-ubiquitin
pathway (shown in red). The stress response in K13 mutants is enhanced (shown in blue). In contrast, epoxomicin inhibits the stress response (shown in
green), thus promoting parasite death.
doi:10.1371/journal.pbio.1002132.g008
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K13 shares some sequence similarity with KEAP1 and KLHL8, which are involved in E3
ubiquitin ligase complexes that regulate the cytoprotective and developmental responses in
mammalian systems [56]. A recent transcriptomic analysis showed up-regulation of the un-
folded protein response in K13 mutant parasites, including genes involved in protein folding,
unfolded protein binding, protein export, post-translational translocation, signal recognition
particle, endoplasmic reticulum retention sequences, the proteasome, and the phagosome [32].
Taken together with our data, this strongly indicates a role for enhanced proteostasis mecha-
nisms as the basis for ART resistance in P. falciparum.
The transcriptomic analysis of Mok et al. also suggested that, at a population level, resistant
parasites exhibit decelerated development at the ring stage. We found that parasites (e.g. PL1
and PL2) that exhibit similar lifecycle profiles (as judged by Giemsa analysis) can have very dif-
ferent responses to ARTs. This indicates that while decelerated development may be a contrib-
utor, other factors are also important. Further work is required to fully elucidate the role of
K13 in enhancing the cell stress response.
Importantly, our work suggests that a proteasome inhibitor could be used to synergize the
activity of ARTs in vivo, and potentially to overcome resistance. Carfilzomib and Bortezomib
are FDA-approved for the treatment of multiple myeloma [57] and inhibitors that specifically
target the plasmodial proteasome have been identified [39,58,59]. These compounds show low
toxicity in human cell lines [59] and limited toxicity in mice [40,58]. In agreement with previ-
ous reports, we find that Carfilzomib shows only weak antimalarial activity, when used alone,
against the ring-stage of a mouse model of malaria [40]. In contrast we observed marked syner-
gism of the action of DHA by Carfilzomib, against P. berghei in vivo, particularly in reducing
the parasite burden in reticulocytes, the preferred host blood cell. While further work is needed
to determine the efficacy of proteasome inhibitors as ART-synergizing-agents in patients, this
work offers a potential avenue to overcome ART resistance.
We analyzed the concentration and exposure-time—dependence of the response of K13 mu-
tant and wild-type parasites in terms of the CEDmodel, enabling for the first time prediction of
in vivo parasite clearance profiles from in vitro assessments of ART sensitivity. Our modelling
indicates that slower in vivo clearance of resistant strains may reflect both decreased killing of
parasites and a slower rate of clearance of parasites that have been rendered unviable. Prolonged
circulation of unviable (but morphologically unchanged) ring-stage parasites will complicate
the analysis of Giemsa-stained peripheral blood smears. This should be considered in the analy-
sis of parasite clearance curves in surveillance studies. While current methods for monitoring
clearance curves are adequate for detecting reduced sensitivity of infecting parasites, they largely
reflect parasite killing during the first treatment dose and may not be suitable for evaluating the
effectiveness of new antimalarials or alternative treatment regimens. For example, our simula-
tions predicted that splitting the ART dose would substantively decrease the level of viable para-
sites but would have no effect on parasite clearance curves. This suggests that a recent clinical
study of a split-dose regimen [49] may have underestimated its effectiveness.
Methods enabling direct monitoring of parasite viability after ART treatment are needed.
Our simulations suggest that a suitable parameter to measure is the fraction of circulating via-
ble parasites at a time point 3 h after the commencement of treatment. Our data suggest that
culturing drug-exposed ring-stage parasites in a drug-free environment for 35 h will enable the
ready distinction of the viable (trophozoites) from non-viable (rings and pyknotic) parasites
and readily distinguish K13 wild-type from mutant parasites. We anticipate that this approach
can be made field-adaptable by culturing washed blood collected from patients 3 h after treat-
ment. Assessment of parasites with a trophozoite-like morphology after 30–40 h in culture
would provide a robust and direct measure of the likelihood of treatment failure.
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Another important implication of our findings is that extended ACT treatment courses
could reduce the viable parasite load to curative levels in ART-resistant falciparum malaria,
since further parasite maturation on the fourth day of treatment will render them much more
sensitive to ART. This is consistent with recent trial data [13] showing 97.7% efficacy of a six-
day treatment course, and adds further support to calls for urgent testing of extended treat-
ments in affected areas. The implementation of new treatment regimens could help battle ART
resistance. This is critical, given that a recent modelling study suggest that even a 30% ACT fail-
ure rate worldwide would result in more than 116,000 additional deaths per year, and US$385
million of annual productivity losses [60].
Materials and Methods
Isolation and Culture Adaptation of Cambodian P. falciparum Strains
P. falciparum isolates were collected from adult patients enrolled in clinical trials conducted be-
tween 2009 and 2010 in Pailin Referral Hospital in western Cambodia as described previously
[21]. Strains were adapted to cultivation in vitro in RPMI supplemented with glutamine and
10% human serum. K13 propeller genotyping of strains were performed as previously de-
scribed [21]. Parasite lines were expanded and aliquots frozen. All analyses were performed
within 4 wk of thawing. All strains are independent isolates based on typing of MSP1, MSP2,
and GLURP, and all exhibit a PfCRT mutant genotype (CVMNT), as typical for this region
[21,61]. A slow-clearance isolate from Pursat province in Cambodia (RF967/ Cam3.II), harbor-
ing the R539T mutation, and a cloned reverted line (Cam3.IIrev), carrying the wild-type allele,
were generated as described elsewhere [20]. In vitro culturing, including generation of very
tightly synchronized cultures, was carried out as previously described [14,28]. All data pre-
sented pertains to cultures synchronized to a 1-h window. The parasite ages defined corre-
spond to the average post-invasion (p.i.) age at the beginning of each drug pulse. Parasite age
distributions during the schizont-to-ring transition were quantitated from Giemsa smears by
periodically examining the number of schizonts and rings of untreated cultures during the
transition, as previously described [14].
Preparation of DNA and Genome Sequencing
Genomic DNA was extracted using the ISOLATE II Genomic DNA kit (Bioline, United King-
dom). Genomic DNA (200 ng) was sheared using an ultrasonicator, and Illumina TruSeq
Nano DNA library preparation was carried out according to the Manufacturer’s instructions.
The libraries were pooled and run with paired-end 300 bp reads on a MiSeq platform over 600
cycles of sequencing using the MiSeq Reagent kit v3 (Illumina, United States). All raw reads
have been submitted to the European Nucleotide Archive (ENA) under the accession number
PRJEB8074. Following adapter trimming, the raw reads were mapped to the reference 3D7 ge-
nome (version 3.0) using BWAmem and filtered for mapping quality score of at least 30. Du-
plicate reads were marked and removed using SAMtools and Picard, and the reads were
realigned around INDELS using Genome Analysis Tool Kit (GATK) RealignerTargetCreator
(Broad Institute, US). Following recalibration of base quality scores, SNPs were called using
GATK UnifiedGenotyper, and hard-filtering of SNPs was performed to obtain high-quality
variants. SNPs that failed any of the following cut-off filters were removed from the analysis:
depth of read<5, variant quality as function of depth QD<2.0, strand bias (P)<10-6, mapping
quality<40, MappingQualityRankSum<−12.5, ReadPosRankSum<−8.0. Genetic variants
were annotated using snpEFF.
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Assessment of Parasite Viability and Drug-Induced Growth Effects by
Flow Cytometry
Drug pulse assays used to estimate LD50 and Vmin have been described previously [14,28]. Para-
site viability following a drug pulse is defined as the fraction of the parasite population that sur-
vives drug exposure and is able to enter the next parasite cycle. Viability was determined by
measuring the parasitemia in the parasite cycle following the drug pulse. For this, parasites
were fluorescently labelled with the RNA-binding dye SYTO-61 and the parasitemia quantitat-
ed by flow cytometry [62]. Viability was calculated in relation to parasitemia in the "untreated
parasite" control (parasites not exposed to drug) and "kill" control cultures. The latter refer to
parasites maintained under constant drug pressure (>100 times the LD50(48 h)) for 48–96 h to
ensure quantitative killing of parasites. The sensitivity limit for viability using this assay is 5%.
LD50 is the drug concentration producing 50% viability. Vmin is defined as the viability at satu-
rating drug concentration and was established by examining viability at the highest drug con-
centration employed in a particular assay.
SYTO-61 labelling of parasites was also used to measure growth effects related to drug treat-
ment. Such measurements require labelling to be performed when the untreated parasite con-
trol culture has progressed to mid-–late trophozoite stage in the cycle following the drug pulse.
This ensures that the SYTO-61 signal from viable parasites exhibiting growth effects show a
measurable decrease compared to the no drug control. The SYTO-61 frequency histogram at a
particular drug concentration was corrected for the presence of unviable/dead parasites by sub-
tracting the appropriate amount of the "kill" control histogram based on the measured viability
at that drug concentration. Corrected SYTO-61 signals refer to the median value of the viable
parasite population and were calculated from the corrected histograms, and are only reported
for sample measurements exhibiting the following criteria: parasitemia>0.3%, number of par-
asites measured>500, and fraction of total parasites measured that are viable>0.7.
Ubiquitinated Protein Analysis
Trophozoite-infected RBCs (25–35 h) or uninfected RBC (3% hematocrit) were incubated with
6 μMQHS or 20 nMWR99210 for 90 min at 37°C. Cells were pelleted, washed three times in
PBS supplemented with anti-protease mixture (APM), 20 mM N-ethylmaleimide (NEM), 2
mM PMSF, 0.5 mM EDTA, and complete mini EDTA-free protease inhibitor mixture (Roche).
Cell pellets were resuspended in 10 volumes of 0.15% (w/v) saponin in PBS for 10 min on ice.
Cells were pelleted and washed twice with PBS + APM. Parasite pellets were subjected to
SDS-PAGE (4%–12% acrylamide; Life Technologies), transferred to nitrocellulose (iBlot, Life
Technologies), and probed with polyclonal rabbit anti-ubiquitin IgG (Z 0458, Dako, 1:100 dilu-
tion in PBS), followed by goat anti-rabbit IgG coupled to horseradish peroxidase. Chemilumi-
nescence was detected using a LAS-3000 Imaging System. Membranes were stripped with 0.2
M glycine, 0.1% (w/v) SDS, 0.01% (v/v) Tween-20, pH 2.2, and re-probed with rabbit anti-
PfGAPDH [63]. Initial control experiments compared the signal in uninfected RBCs and very
early ring-stage—infected (1–2 h p.i.) RBCs (5% parasitemia). Densitometric analysis of the re-
gion of the gel between 80 and 200 kDa was performed using ImageJ software. The data were
corrected for background and for loading based on the PfGAPDH signal.
Mouse Studies
Mice were housed with strict temperature control (21°C) and under a 12:12 light:dark cycle.
All mouse experiments were approved by the Animal Ethics Committee at Macquarie Univer-
sity (ARA 2012/018) and conformed to the National Health and Medical Research Council
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guidelines. For rodent malaria infection, 250 μl of thawed P. berghei ANKA parasitized blood
were intraperitoneally injected onto SJL donor mice. Once the donor mice reached 5%–15%
parasitemia, the mice were exsanguinated and the blood was diluted in Kreb’s buffered saline
[64] at a dose 1x106 parasitized RBCs. The parasitized RBCs were injected into the peritoneal
cavity of BALB/c female mice. After inoculation, the mice were monitored daily or twice daily
using tail bleed smearing or flow cytometry using JC-1 dye gated on TER119, cd71, and cd45
[65]. For the drug administration, infected BALB/c mice (~21 g) were treated with intravenous
doses of Carfilzomib (0.5, 1, and 1.5 mg/kg), intra-peritoneal doses of DHA (5, 10, 15, and 20
mg/kg), a combination of Carfilzomib and DHA (5 or 10 mg/kg of Carfilzomib, with respec-
tively 5 and 10 mg/kg of DHA), or vehicle (10 mM citrate buffer, 20% Kleptose for Carfilzomib
and 60% dimethyl sulfoxide, 40% Polysorbate 80 for DHA). The mice were drug-injected for
three consecutive days, starting day 3 post-inoculation. A Student’s one tailed t test was per-
formed and corrected with a Bonferroni procedure for multiple testing to investigate the statis-
tical differences between drug treatments.
Kinetic Data Analysis and Simulations
Parasite viability (V) as a function of drug concentration (C) and drug exposure time (te) were
analyzed according to the CED model [14]:
VðC; teÞ ¼ 1þ Ct
e
te;sat50 ðKm þ CÞ
 g 1
where Km is the drug concentration resulting in half the maximum effective dose, γ is the slope
of the sigmoidal function, and te;sat50 is the minimum time required to kill 50% of the parasites
(at saturating drug concentrations). The model was ﬁtted to the data, using Microsoft Excel
with the Solver add-in. The method employed for simulating parasite load during a three-day
course of ART monotherapy is presented in S1 Appendix. An Excel spreadsheet for the simula-
tion of parasite clearance is also supplied (S1 Spreadsheet).
Supporting Information
S1 Appendix. Simulation of in vivo parasitemia during DHAmonotherapy and split-dose
therapy.
(PDF)
S1 Data. Numerical values for all figures.
(XLSX)
S1 Fig. Effect of drug exposure time on dose response profiles of PL2 (wild-type) and PL7
(R539T) strains.Measurements were carried out as described in Fig 1C, by exposing parasites
of defined ages to DHA for the time periods indicated in the legends. Viability is defined as the
fraction of the parasite population that survives drug exposure and is able to enter the next par-
asite cycle. The parasites were early rings (2 h p.i., top panel), rings (7 h p.i., middle), or tropho-
zoites (34 h p.i., bottom). Solid curves represent the best fits with the CEDmodel parameters
shown in Table 1. Reliable parameters could not be obtained with the set of measurements rep-
resented by the dashed line because the drug dose was already saturating at the shortest expo-
sure time (30 min). Error bars correspond to the range of duplicates.
(TIFF)
S2 Fig. Interaction of epoxomicin with DHA in PL2, PL5, and PL7 strains at different
stages. PL2 (A), PL5 (B), and PL7 (C) parasites at different stages (indicated by their p.i. age)
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were subjected to 3-h pulses in the presence of different combinations of DHA and epoxomicin
(Epo). The left side of each panel shows the influence of sublethal concentrations of epoxomi-
cin (indicated in figure) on the dose-response profile of DHA (blue symbols). The right side of
each panel presents the isobolograms for the epoxomicin-DHA pair at the 50% LD50 level. The
dashed line is plotted between the LD50 of each drug used alone, emphasizing the concave na-
ture of many of the isobolograms. The absence of a line indicates the LD50 value of one of the
drugs was outside the range of concentrations examined. Error bars, where present, correspond
to the range of duplicates.
(TIFF)
S3 Fig. Interaction of epoxomicin with DHA in the matched K13 mutant and wild-type
transfectants strains. Cam3.II (R539T) (A) and a reverted transfectant in which the K13 wild-
type genotype has been restored (Cam3.II_rev) (B) were synchronized to a 1-h window and
subjected to 3-h pulses in the presence of different combinations of DHA and epoxomicin
(Epo) at the following times p.i.: 1 h (very early ring, vER), 7 h (ring, R), and 27 h (troph, T).
The left panels show the dose-responses to DHA and the influence of sub-lethal concentrations
(indicated) of epoxomicin. The right panels show the isobolograms for the epoxomicin-
DHA pairs at the 50% lethal dose level. Error bars, where present, correspond to the range
of duplicates.
(TIFF)
S4 Fig. Interaction of carfilzomib with DHA in PL2, PL1, PL7, and PL5 strains at different
stages. PL2 (A), PL1 (B), PL7 (C), and PL5 (D) parasites at different stages (indicated by their
p.i. age) were subjected to 3-h pulses in the presence of different combinations of DHA and
carfilzomib (Carf). The left side of each panel shows the influence of sublethal concentrations
of carfilzomib (indicated in figure) on the dose-response profile of DHA (blue symbols). The
right side of each panel presents the isobolograms for the carfilzomib-DHA pair at the 50%
LD50(3h) level. The dashed line is plotted between the LD50(3h) of each drug used alone, em-
phasizing the concave nature of many of the isobolograms. The absence of a line indicates the
LD50(3h) value of one of the drugs was outside the range of concentrations examined. Error
bars, where present, correspond to the range of duplicates from an experiment performed
in singlicate.
(TIFF)
S5 Fig. Interaction of Bortezomib with DHA in the PL7 strain at the trophozoite stage. PL7
parasites (3-h window, mid-trophozoites) were subjected to 3-h pulses in the presence of differ-
ent combinations of DHA and Bortezomib (Bort). The left panel shows the dose-responses to
DHA (diamonds) and the influence of sub-lethal concentrations (indicated) of Bortezomib.
The right panel shows the isobologram for the Bortezomib-DHA pair at the 50% lethal dose
level. Error bars, where present, correspond to the range of duplicates.
(TIFF)
S6 Fig. In vivo synergy between DHA and Carfilzomib against infected reticulocytes. Balb/c
mice were infected with 106 parasites (P. berghei) and treatment was initiated at ~1% parasitae-
mia (i.e., day 3), indicated with an arrow. (A) Delivery of vehicle alone is associated with high
parasitemia (in RBCs), while DHA alone has a significant effect on parasite burden at all doses.
(B) The same data displayed on an expanded scale reveals that drug treatment with DHA at
doses 5 and 10 mg/kg has a moderate effect on parasite growth, whereas the doses 15 and 20
mg/kg totally abrogate parasite growth. (C) DHA (5 mg/kg) + Carfilzomib (0.5 mg/kg) mod-
estly prevents parasite growth in reticulocytes, whereas DHA (5 mg/kg) + Carfilzomib (1 mg/
kg) drastically reduces the parasite burden after treatment. (C) DHA (10 mg/kg) + Carfilzomib
Targeting Artemisinin-Resistant Plasmodium
PLOS Biology | DOI:10.1371/journal.pbio.1002132 April 22, 2015 22 / 26
(0.5 or 1 mg/kg) abrogate the growth of P. berghei parasites in reticulocytes. Error bars repre-
sent SEM, and  and  represent, respectively, p< 0.05 and p< 0.01 after Bonferroni correc-
tion for multiple testing.
(TIFF)
S7 Fig. Age distribution (simulated from model) of viable parasites during the course of
drug treatment (0, 24, 48, and 72 h post initial dose) for the PL2 (red) and PL7 (blue) infec-
tions presented in Fig 7.
(TIFF)
S8 Fig. Measurement of the circulating viable fraction during ART therapy can distinguish
between sensitive and resistant strains. Simulations for PL2 (red) and PL7-like (blue) infec-
tions were performed as described in Fig 7 but using various values for Cmax (0.5, 2, and 20 μM
corresponding to dotted, dashed, and solid lines, respectively). The circulating viable fraction
at each time is the total number of circulating viable parasites divided by the total number of
circulating parasites (i.e., including unviable parasites). Arrows indicate that this parameter at
3 h is insensitive to the value of Cmax and can distinguish between the two strains.
(TIFF)
S1 Spreadsheet. Excel Spreadsheet for simulation of parasite clearance curves. The Parasite
Clearance Simulation can be downloaded as a separate file.
(XLSX)
S1 Table. Parameters relating to the quality of the Illumina MiSeq genome sequence data.
(PDF)
S2 Table. SNP analysis of Pailin strains at loci reported to be associated with differences in
ART sensitivity. Kelch 13 (K13), P. falciparumMulti-Drug Resistance Gene-2 (MDR2), apico-
plast ribosomal protein (ARPS10), ferredoxin (FD), PfCRT, protein phosphatase (PPH), phos-
phoinositide-binding protein (PIB7), Multi-Drug Resistance Gene-1 (MDR1), Ubiquitin
Binding Protein-1 (UBP1), Multidrug Resistance Protein-1 (MRP1), cyclic nucleotide-binding
protein (cNBP) and the 30 UTR of the DNA polymerase catalytic subunit. No artemisinin resis-
tance associated mutations were observed in RAD5 or SERCA.
(PDF)
S3 Table. Parameters used in simulation presented in Fig 7A.
(PDF)
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